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Background: Glanders is a contagious and fatal zoonotic disease of solipeds caused by the Gram-negative
bacterium Burkholderia (B.) mallei. Although regulations call for culling of diseased animals, certain situations
e.g. wild life conservation, highly valuable breeding stock, could benefit from effective treatment schemes and
post-exposure prophylaxis.
Results: Twenty three culture positive glanderous horses were successfully treated during a confined outbreak by
applying a treatment protocol of 12 weeks duration based on the parenteral administration of enrofloxacin and
trimethoprim plus sulfadiazine, followed by the oral administration of doxycycline. Induction of immunosupression
in six randomly chosen horses after completion of treatment did not lead to recrudescence of disease.
Conclusion: This study demonstrates that long term treatment of glanderous horses with a combination of various
antibiotics seems to eliminate the agent from the organism. However, more studies are needed to test the
effectiveness of this treatment regime on B. mallei strains from different endemic regions. Due to its cost and
duration, this treatment can only be an option in certain situations and should not replace the current “testing and
culling” policy, in conjunction with adequate compensation to prevent spreading of disease.
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Glanders is a contagious and highly fatal zoonotic dis-
ease of solipeds caused by the Gram-negative bacillus
Burkholderia (B.) mallei. This disease is characterised by
progressive loss of efficiency due to the development of
nodular and ulcerative lesions in the skin and the upper
respiratory tract. The horse is the only known natural
host of B. mallei. In humans, glanders is usually an oc-
cupational disease, affecting individuals in close contact
with infected animals such as farmers, grooms, and
veterinarians, but also laboratory personnel handling the
agent. Glanders has a 95% case fatality rate in untreated
septicaemic infections and a 50% case fatality rate in
treated human individuals, even if diagnosed early on
[1,2]. Despite several studies demonstrating the suscepti-
bility of B. mallei to numerous antibiotics in vitro, many* Correspondence: natter13@gmx.de
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reproduction in any medium, provided the orfailed to eradicate the agent from the organism of
laboratory animals when challenged [1,3,4]. Current
treatment protocols for human glanders therefore, are
based on data gained from treatment schemes for
melioidosis, a disease caused by the closely related agent
B. pseudomallei, using a combination of antibiotics for
an extended period of time.
In Pakistan, legislation based on the “Glanders and
Farcy Act of 1899” calls for the detection and destruc-
tion of glanderous animals [5]. However, although ani-
mal owners are paid compensation for having their
animals culled, the sum is so ridiculously low (~50 PKR;
~0.42 €; ~0.53 US$) that owners prefer to sell their ani-
mals beforehand and thereby risk the introduction of
disease to hitherto glanders-free regions [6,7]. In view of
the difficulties involved in the implementation of regula-
tions in many countries, it thus seems reasonable to
re-evaluate the role of [modern] chemotherapy as a
possible alternative to culling. Effective treatment schemes
and post-exposure prophylaxis are urgently required espe-
cially in equestrian sport and breeding where highlytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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demic countries and vice versa. Finally, although public
health must be paramount, greater emphasis has to be
placed upon animal welfare and new guidelines developed
and implemented in the treatment and prevention of ani-
mal disease [8].
The present report describes a treatment protocol of
12 weeks duration based on the parenteral administra-
tion of enrofloxacin and trimethoprim + sulfadiazine,
followed by the oral administration of doxycycline du-
ring a confined glanders outbreak in horses in Lahore,
Pakistan.Animals, materials and methods
Study animals and study area
Twenty three horses (15 male, 8 female; median age 3.5
year; median body weight 340 kg) were found to have
contracted glanders during an outbreak at the Lahore
Polo Club (LPC) in Lahore, Pakistan in 2005 (Table 1).
Questioning of the staff revealed that all affected horses
had drunk water from a common water trough. After
cultural and diagnostic confirmation of glanders by






1 f 6 367 English 1 4
2 g 7 371 Thorough 2 3
3* g 6.5 316 ND 3 2
4 f 5 360 Thorough 1 4
5 m 8 347 Anglo-Arab 2 2
6* f 5.5 371 Thorough 2 3
7* g 6 328 Arab 3 2
8* f 5 353 Thorough 1 4
9 g 3.5 339 Arab 2 3
10 m 7 370 ND 2 3
11 g 5 332 Arab 3 2
12 g 5 340 Arab 1 3
13 m 8.5 365 Thorough 2 3
14 g 7.5 340 Thorough 3 2
15 m 7 359 Thorough 2 4
16# f 5 370 Thorough 1 4
17 g 7 319 Anglo-Arab 3 2
18 f 5.5 373 Anglo-Arab 2 4
19 f 4.5 310 Arab 3 2
20* g 5 368 Arab 1 4
21 g 6 348 Anglo-Arab 2 3
22* f 6 329 Arab 4 2
23 g 7 370 Thorough 1 5
M male, g gelding, f female, * euthanized horses, # aborted during treatment, NS na
PTC pulmonary tissue calcification, LPC Lahore Polo Club, LFU Lost during follow-uphorses were transferred to the Department of Clinical
Medicine and Surgery (CMS), University of Agriculture
(UAF), Faisalabad, Pakistan for experimental therapy.
During the treatment period, the horses were managed at
the Large Animal Indoor Facility of the Department. The
facility was declared off-limits for all personnel other than
the investigators and attendants of the equines; relevant
bio-security measures were initiated.
Animal ethical issues
The present study was approved by the Synopsis Scrutiny
Committee and the Animal Ethics Committee, Faculty of
Veterinary Science, UAF, Faisalabad, Pakistan. Permission
for the experimental treatment was additionally granted
by the Secretary of Livestock and Dairy Development,
Government of Punjab, Pakistan.
Bacteriological cultivation and identification of B. mallei
Culture and identification of B. mallei was performed as
described previously [11] Briefly, nasal swabs, nodule
aspirates and venous blood samples collected from the
horses were plated onto brain heart infusion agar (BHI;








1 NS, CN LPC§
1 NS, CN LFU
2 NS, CN;VB PTC -
1.5 CN LPC
2 NS, CN LFU
2.5 NS, CN
1 NS, CN PTC -
2 NS PTC -
2 NS, CN LFU
2 NS, CN LFU
2 NS, VB LPC
2 NS LFU
1.5 NS LFU
2 NS, VB LPC
1 NS LFU
1 NS LFU
3 NS, CN LPC
1 NS LPC
2 NS, CN LFU
5 d NS -
1.5 NS, CN LPC
3.5 NS, CN, VB PTC -
1 NS LFU
sal discharge swab, CN cutaneous nodule aspirate, VB venous blood sample,
, § 2 foals since 2007.
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MacConkey agar (Oxoid Limited). In order to minimise
contamination, each nasal swab was incubated at room
temperature in distilled water containing 3000 IU/mL
benzyl penicillin for 3 h prior to plating. Culture plates
were incubated at 37°C under aerobic conditions for
72 h. Representative colonies of B. mallei were screened
for Gram staining, catalase, indole tests, and colistin re-
sistance. The organism was presumptively identified as
B. mallei if bipolar, catalase positive, indole negative,
colistin resistant and if an irregularly, Gram-negative
stained rod. Isolates were then subjected to motility test-
ing, triple sugar iron slants (Oxoid Limited) and API
20E (Bio Mérieux, Craponne, France). Non motile, triple
sugar iron negative, arginine, and gelatine positive iso-
lates were finally identified as B. mallei.
Susceptibility testing, antibiotics, dose, and treatment
regime
Antibiotics were selected on the basis of susceptibility
testing by means of the disc diffusion method [12]. In
brief, MIC values of 41 B. mallei isolates from various
Glanders outbreaks in the Pakistani Punjab including
those from the present outbreak were determined by agar
dilution for 20 different antimicrobials: ampicillin, amo-
xicillin, co-amoxiclav, ceftiofur, doxycycline, oxytetracy-
cline, cephradine, ceftriaxone, ciprofloxacin, sulphadiazine
(SDZ), trimethoprim, roxithromycin, clarithromycin, cefo-
taxime, cefuroxime, ciprofloxacin, enrofloxacin, norfloxa-
cin, and chloramphenicol. The isolates were susceptible to
amoxicillin-clavolanic acid, doxycycline, chlorampheni-
col, gentamycin, and trimethoprim-sulphadiazine. The
isolates obtained from the horses of the present study
were additionally resistant to enrofloxacin. Mode MICs
for these antimicrobials were 2, 1, 8, 4, 1, and 2 mg/mL,
respectively [11].
A twelve week course of antibiotics was applied. In
week 1, horses were treated intravenously with 8 mg/kg
body weight enrofloxacin (Enrotil 10%, Dae Sung Micro-
biological Labs, Korea) and 32 mg/kg body weight Tri-
brissenW 48% (trimethoprim (TMP) + sulphadiazine;
Glaxo-Smith-Kline, Pakistan) once a day. In weeks 2 and
3, the dosage was halved to 4 mg/kg body weight enro-
floxacin and 16 mg/kg body weight TribrissenW 48%.
During weeks 4–12, the horses were given 6 mg/kg body
weight doxycycline orally (Doxy-veto, VMD, Arendonk,
Belgium) twice a day.
Recording of clinical signs
Clinical signs such as fever, inappentence, debility,
cough, dyspnoea, nasal discharge, development and loca-
tion of ulcers, adspection of lymph nodes and lymphatics
were recorded prior to (d 0), during and after treatment
(Table 2).Assessment of treatment response
Response to treatment was evaluated by means of daily
monitoring and recording of rectal temperature, pulse,
and respiration rates during parenteral therapy. Changes
in nutritional status were calculated by means of body
condition scores (BCS) for equines according to
Henneke et al., [13]. These scores were then juxtaposed
to the clinical severity score (CSS) associated with the
health status at day 0 (i.e. prior to treatment) and at
intervals of 60 days during and up to 1 year after treat-
ment. Blood analyses were carried out at day 0 prior to
treatment for base line values, at completion of treat-
ment (d 84) and then at 90 day intervals during the one
year follow-up period according to the procedures pre-
viously described [14]. Indirect haemagglutination
assays (IHA) using B. mallei strains PRL4, PRL7 and
China 5 [11] were carried out on d 0 (prior to malleini-
sation), during treatment and then at 30 day intervals
throughout the follow-up period (Table 3).
Assessment of absence of disease
Horses were observed for recrudescence of disease du-
ring the one year follow-up period. The study animals
were subjected to a mallein test at completion of treat-
ment (day 84) and at the end of the one year follow-up
period. Additionally, on day 90, six horses were im-
munocompromised by daily intramuscular administra-
tion of 14 mL Penacort (2.5 mg Dexamethasone + 7.5 mg
Prednisolone/mL; Selmore Pharmaceuticals, Pakistan) for
10 days. Horses were exercised twice daily for one hour.
On days 100, 102 and 104, two horses each were eutha-
nized by the i. v. administration of sodium pentothal
(3 g; Thiopental, Rotexmedica, Trittau, Germany) and
magnesium sulphate (200 g; Shamsi Pharmacy, Lahore,
Pakistan). In order to exclude the possibility of carrier
status among the treated horse, 110 clinically healthy,
glanders negative, i.e. mallein test negative sentinel horses
were housed with the treated horses during the one year
follow-up period.
Bacterial cultivation upon necropsy
From the six euthanized horses, tissue samples were
taken aseptically from the mediastinal and submandibu-
lar lymph nodes, as well as from the lung. Bacterial cul-
tivation was carried out as previously described [9-11].
Briefly, ~7 g tissue slices were placed in 5 mL PBS and
homogenised using a Pyrex Potter-Elvehjem tissue hom-
ogeniser with a PFTE pestle (17 mL capacity; Corning,
Lowell, MA, USA). From this homogenate 5 mL tripli-
cates were subsequently cultured in 100 mL BHI plus
2% glycerol (UH0, Oxoid Limited), containing 100 U/mL
penicillin G, and 10 U/mL colistin sulphate (both Sigma
Aldrich, Taufkirchen, Germany) for 56 h at 37°C. Next,
200 μL from this broth were inoculated in duplicate on
Table 2 Clinical signs observed in polo horses with glanders during the study period








# % # % # % # %
a) Fever 22 95.6 - - - - -
mild (38.9-39.4°C; 102.0 -102.9°F)
moderate (39.5-40.0°C; 103.1-104.0°F)
b) Inappentence 23 100 - - - - - -
c) Debility 23 100 - - - - - -
d) Quick loss of stamina (when put to work,
exercised or driven)
23 100 - - - - - -
f) Cough 14 60.9 - - - - - -
g) Dyspnoea 16 69.6 - - - - - -
h) Abnormal respiratory sounds (audible
at a distance)
10 43.5 - - - - - -
i) Nasal discharge 18 78.3 - - - - - -
- Uni-lateral 10 43.5 - - - - - -
- Bilateral 8 34.8 - - - - - -
- Without blood 4 17.4 - - - - - -
- With blood 14 60.9 - - - - - -
- Occasional epistaxis (when put to work,
exercised or driven)
6 26.1 - - - - - -
j) Nasal septum ulcers 16 69.6 - - - - - -
k) Nodules and crater-like ulcers 20 86.9 - - - - - -
- Medial aspect of thigh 14 60.9 - - - - - -
- Perianal region 6 26.1 - - - - - -
- Groin 6 26.1 - - - - - -
- Below hock 6 26.1 - - - - - -
- Foreleg 2 8.7 - - - - - -
- Achilles tendon 2 8.7 - - - - - -
- Face 4 17.4 - - - - - -
- Testes 4 17.4 - - - - - -
- Distributed almost all over the body 4 17.4 - - - - - -
l) Orchitis 4 26.6 - - - - - -
m) Enlargement of submaxillary lymph nodes 23 100 - - - - - -
- Enlargement visible from a distance 4 17.4 -* - - - - -
- Enlargement detectable only on palpation 20 86.9 -* - - - - -
n) Cording of lymphatics 10 43.5 - - - - - -
- Inner aspects of thigh 6 26.1 - - - - - -
- Latero-medial aspects of trunk and abdomen 4 17.4 - - - - - -
o) Oedema of hind legs 8 34.8
#: number of horses affected; *: tortuous, palpably enlarged; - not observed.
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blood and incubated for 6 days at 37°C.
Results
Isolation of B. mallei from clinical samples
B. mallei was isolated from 22/23 nasal swabs, 13/23
aspirates from cutaneous nodules and 4/23 venous blood
samples (Table 1).Clinical signs observed in the horses throughout the
study period
Clinical signs in the diseased horses were recorded at
the time of diagnosis (d 0), during treatment (parenteral
& oral), at 6 months after treatment and during the 1
year follow-up observation period (Table 2). Prior to
treatment fever was observed in 22/23 horses, inappen-
tence in 23/23, debility in 23/23, loss of stamina in 23/
Table 3 IHAT antibody titres of polo horses with glanders during the study period
Treatment period (months) n = 23 Post treatment observation period (months) n = 17
titer d0# 1 2 3 (d 84) 1 2 3 4 5 6 7* 8 9 10 11 12
1:40 - - - - - - - - - - - - - - - -
1:80 - - - - - - - - - - - 2 2 6 7 8
1:160 1 - - - - - - - 1 - 5 12 15 11 10 9
1:320 - - - - - - 6 14 11 15 10 3 - - - -
1:640 7 - - 8 1 7 11 3 5 2 - - - - - -
1:1280 10 6 12 8 10 9 1 - - - - - - - - -
1:2560 4 10 11 7 6 - - - - - - - - - - -
1:5120 - 4 - - - - - - - - - - - - - -
1:10240 1 3 - - - - - - - - - - - - - -
1:20480 - - - - - - - - - - - - - - - -
#prior to malleinisation; *values missing due to loss of samples.
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in 18/23, nasal septum ulcers in 16/23, nodules and
ulcers on the body in 20/23, orchitis in 4/23, enlarge-
ment of submaxillary lymph nodes in 23/23 and cording
of lymphatics of hind limbs and ventro-lateral abdomen
in 10/23 horses.
After the first week of treatment, the clinical picture
improved visibly. Fever subsided and only slightly
increased rectal temperature was observed in 9/23
horses (Table 4). Horses began to regain their appetite,
respiration rates started improving with 10/23 showing
physiological values (Table 5). By the end of treatment
week one, nasal septum ulcers had healed in 16/16
horses and the oedema in the hind legs were only
slightly visible in the eight affected horses. Nodules and
ulcers were cleared in 19/20 horses and by the end of
treatment week three in all horses (Table 2). Pulse rates
returned to physiological values by the end of treatment
week two in 22/23 horses (Table 6). With completion of
treatment week three, moderately enlarged submaxillary
lymph nodes were still palpable in 19/23 horses; all ani-
mals showed regular food intake. After treatment week
12, no clinical signs were observed in any of the horses;
however, enlarged lymph nodes were still palpable in
9 horses (Table 4).
Of note is that on treatment day 11 one horse became
restless and showed signs of muscular fasciculation in
the forelimbs during the application of TribrissenW 48%.
The injection was stopped immediately. The adverse re-
action subsided within three hours and the horse was
re-injected three hours later. All horses developed alope-
cia on the trunk and neck during the second week of
treatment. Hair growth resumed on week 2 after termi-
nation of intravenous therapy. One mare, whose preg-
nancy had gone unnoticed, aborted on treatment day
17. No foetal abnormalities were observed.Correlation between body condition scores and clinical
severity scores
Body condition scores (BCS) recorded at presentation of
the animals (d 0) revealed 8 horses with a score of 2, 7
horses with a score of 3, 7 horses with a score of 4 and
one horse with the score of 5. With the progression of
treatment and time, BCS rose and remained stable at
values between 4 and 5. Clinical severity scores (CSS)
recorded on day 0 were distributed as follows: Seven
horses showed a score of 1, 9 horses a score of 2, 6
horses a score of 3 and 1 a score of 4. From day 60 on-
wards, all horses showed a CSS of 0 (Tables 1, 7 and 8).
Induction of immunosupression
On day 90, after completion of therapy, six randomly
selected horses were treated daily for 10 days with corti-
costeroids to induce immunosupression. During the 14
d observation period, no recrudescence of clinical signs
was observed.
Pathology and bacteriology
Necropsy revealed non specific findings, except for
discrete calcified lung lesions, especially at the lower rim
of the cardiac lobe and scarring of the mediastinal lymph
nodes. Samples taken aseptically from the mediastinal
lymph nodes, lungs tissue and from submandibular
lymph nodes were negative for B. mallei.
Haematological analyses
Haematological parameters were assessed in all 23
horses on day 0 (before initiation of treatment), on day
84 and during the one year follow up period (Table 9).
On day 0, all horses showed a significant decrease in
total RBC counts, haemoglobin levels, and PCV values,
but a significantly elevated leukocyte count and an acce-
lerated erythrocyte sedimentation rate when compared
Table 4 Rectal temperatures (°F) during parenteral treatment with enrofloxacin and TribrissenW 48%
Rectal temperature (°F)
Week 1 (d) Week 2 (d) Week 3 (d)
Horse 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
1 104 103.8 103 103.2 102.4 101.2 100.8 100 100.4 Normal body temperature
2 103.2 103.8 102.2 102.8 101.2 102 101.6 100.8 100 Normal body temperature
3 103.4 101.4 101.8 102.6 101 100.8 100.8 100 Normal body temperature
4 100.8 102.4 101 101.8 99.8 100.2 99.8 Normal body temperature
5 102.8 101.6 101.6 101.2 100.2 100.8 100 Normal body temperature
6 101.8 102.4 102 102.6 101.8 101.4 101.2 100.6 99.8 Normal body temperature
7 103 103.2 103 102.8 102 101.8 101.8 101 101.2 100.8 100 Normal body temperature
8 102.4 101.4 101.8 101 101.4 100.2 100.4 100 Normal body temperature
9 103.4 103 102.8 101.6 100.2 100.8 100 Normal body temperature
10 105 103.4 104.2 103 103.6 102.8 101.6 100.8 101 100 100.8 Normal body temperature
11 103.8 101.6 102 99.8 100.2 99.2 100 Normal body temperature
12 102.8 102.6 102.8 101.2 101.6 100.2 100.6 100.2 Normal body temperature
13 104.2 104 104.2 104 103.2 102.6 102 100 99.8 Normal body temperature
14 102.4 101.8 102 101 100 100.8 100.2 Normal body temperature
15 105.6 103.8 102.8 101.6 102 101 100.2 100.6 100.6 Normal body temperature
16 102.2 101.8 101 101 99.8 100.6 99 Normal body temperature
17 106 104.2 103.2 103.8 102.8 103 101 101.8 101.4 101 100.2 100.6 Normal body temperature
18 103.4 103 103.2 102 101.2 101 100.8 100 Normal body temperature
19 104 104.6 103.8 104 102.6 102 102.6 100 99 98.9 Normal body temperature
20 103.6 101 102.2 101 102 102.2 100.2 100.8 100.6 Normal body temperature
21 105.4 103.8 104.8 102.6 103.8 102 101.6 102.2 100 100 Normal body temperature
22 103.6 101.8 102.4 102.4 102 101.8 102 101.8 101.6 99 100.2 Normal body temperature
23 104.6 103.8 102.8 102.6 101.2 100.2 100.8 101 100.4 100 Normal body temperature
*Physiological rectal temperature (°F) in an adult horse: 99–100.5 [15].
Saqib et al. BMC Veterinary Research 2012, 8:214 Page 6 of 11
http://www.biomedcentral.com/1746-6148/8/214to standard hematologic values [14]. When the blood
was subjected to differential leukocyte count, a signifi-
cant increase in neutrophils along with a significant
decrease in lymphocytes was observed, whereas eosino-
phils, monocytes, and basophils were within the nor-
mal range. Calculations of erythrocyte indices revealed
macrocytic hypochromic anaemia (data not shown). In
the course of treatment and during the follow up
period red blood cell count values returned to physio-
logical values. Differential white blood cell counts
revealed an increase of neutrophils at day 360 and an
increase of lymphocytes at day 180 and day 270.Indirect haemagglutination assays
At day 0, prior to malleinisation, 22/23 horses showed
positive titres. Titres shifted during the treatment
period, reaching their peak during the first month.
Titres progressively declined three months after ending
of treatment. Eight months into the observation period
the titres of all horses dropped to values (≤ 1:320)
considered negative for glanders [17] (Table 3).Discussion
Glanders has been eliminated from the western world by
means of a rigorous test and culling policy, frequently
accompanied by sensible compensation schemes [18,19].
However, in countries with low or no compensation, al-
beit strict legislation, implementation of these regula-
tions is extremely difficult, and as a consequence regions
of endemicity may be formed or continue to persist [20].
These regions not only pose a local public health threat
but may also have a major impact on international horse
transportation, especially with regard to equestrian sport
and breeding. Highly valuable animals are regularly
transported to and from endemic regions and thus pose
a risk of reintroduction of disease to so far disease free
areas. Availability of effective treatment schemes and
post-exposure prophylaxis could help to reduce spread
of disease. In recent years, evidence has accumulated
from in vitro antibiotic sensitivity testing and in vivo
treatment studies that certain antibiotics such as enro-
floxacin, erythromycin, doxycycline, and sulphonamides
might be effective against B. mallei [1,21,22]. The
present study therefore, aimed at assessing the
Table 5 Respiration rates during parenteral treatment with enrofloxacin and TribrissenW 48%
Respiration rate (per minute)
Week 1 (d) Week 2 (d) Week 3 (d)
Horse 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
1 20 21 19 18 20 18 18 17 18 16 14 16 18 18 15 12 Normal respiration rate
2 24 19 21 20 19 16 18 12 15 13 Normal respiration rate
3 48 40 46 36 29 24 26 30 22 23 20 15 18 16 16 13 16 Normal respiration rate
4 20 20 18 16 16 11 15 Normal respiration rate
5 33 31 34 32 30 21 20 20 20 21 20 17 13 16 16 14 16 11 14 Normal respiration rate
6 28 21 23 21 17 15 15 10 Normal respiration rate
7 28 32 29 24 24 20 20 21 24 24 20 16 19 15 16 13 15 Normal respiration rate
8 48 32 24 24 24 19 15 16 13 13 Normal respiration rate
9 32 32 32 27 28 20 20 21 20 17 18 18 15 14 Normal respiration rate
10 22 20 16 20 16 15 18 18 14 Normal respiration rate
11 24 24 25 24 20 20 16 13 15 16 13 Normal respiration rate
12 29 32 30 21 28 23 22 21 23 19 21 22 20 20 17 19 18 15 17 11 13 Normal
13 28 29 26 28 27 22 17 20 16 16 15 17 19 18 12 15 Normal respiration rate
14 28 22 22 21 20 18 21 21 18 19 20 20 15 13 12 Normal respiration rate
15 35 36 30 32 28 24 20 19 20 16 17 17 15 13 Normal respiration rate
16 28 21 18 19 13 15 Normal respiration rate
17 20 20 19 20 17 13 15 13 14 Normal respiration rate
18 23 21 21 24 20 18 17 18 18 15 18 20 15 13 Normal respiration rate
19 20 22 20 21 20 20 22 21 18 20 16 16 18 14 15 Normal respiration rate
20 18 18 16 17 16 18 15 17 13 15 Normal respiration rate
21 24 24 24 23 21 20 19 20 18 13 15 12 12 Normal respiration rate
22 28 26 25 22 22 19 20 17 16 15 15 15 Normal respiration rate
23 24 20 20 21 20 16 18 16 15 17 13 12 15 Normal respiration rate
*Physiological respiration rate (breath/min) in an adult horse: 10–15 [15].
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based on the parenteral administration of enrofloxacin
and trimethoprim + sulfadiazine, followed by the oral
administration of doxycycline during a confined glanders
outbreak in horses in Pakistan. Enrofloxacin is a fluoro-
quinolone antibiotic with an antibacterial activity against
a broad range of Gram- positive and Gram-negative bac-
teria. Its mode of action is not fully known, but it is
believed to interfere with bacterial DNA synthesis by
inhibiting bacterial DNA gyrase [23]. Trimethoprim re-
versibly inhibits the bacterial synthesis of tetrahydrofolic
acid, which is essential for the de novo synthesis of
Thymidine monophosphate, a precursor of the DNA me-
tabolite Thymidine triphosphate [23]. Sulfadiazine, like
other sulphonamides, interferes with the bacterial syn-
thesis of dihydrofolic acid, ultimately leading to bacterial
death by starvation [23]. Doxycycline is a semi-synthetic
tetracycline with an antibacterial activity against a broad
range of Gram-positive and Gram-negative bacteria.
Tetracyclines inhibit protein synthesis by binding to
the 30S subunit of susceptible organisms [23].Several rather anecdotal reports describing the suc-
cessful treatment of horses with glanders exist. Early
attempts towards the end of the 19th century and in the
very beginning of the 20th century to “vaccinate” or even
cure horses using mallein or other heat or chemically
inactivated B. mallei preparations, i. e. “anamorve”, and
“farase” did not lead to satisfactory results and were thus
aborted [24,25]. However, a few decades later, new
approaches based on the application of different sulpho-
namides combined with mallein or “anamorve”, i.e. heat-
inactivated, and formolized B. mallei showed a more
promising outcome. Back in 1951, Deyhimi and Katai
succeeded in treating 141 glanderous horses and 18
mules by means of using various sulphonamides (sul-
phathiazole, sulphanilamide, sulphadiazine, sulphame-
zathine) for thirty consecutive days in combination with
“anamorve” or mallein [26]. Subsequent post mortem
studies done 12 and 30 months after end of treatment
on three horses revealed non specific findings and no
cultures could be obtained. Moreover, inoculation of
hamsters with samples obtained from these horses did
Table 6 Pulse rate (beat/min) during parenteral treatment with enrofloxacin and TribrissenW 48%
Pulse rate* (per minute)
Week 1 (d) Week 2 (d) Week 3 (d)
Horse 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
1 48 52 44 40 36 44 40 32 40 36 36 Normal pulse rate
2 68 76 60 60 56 60 44 48 40 40 40 44 32 28 Normal pulse rate
3 80 72 64 72 72 56 60 52 56 48 48 40 36 44 36 40 36 32 40 Normal pulse rate
4 52 48 48 52 44 40 44 40 44 40 36 40 Normal pulse rate
5 64 68 60 60 48 52 52 52 48 44 44 36 40 Normal pulse rate
6 60 68 60 56 60 44 40 48 40 40 Normal pulse rate
7 64 64 64 60 60 52 48 52 56 52 44 44 36 40 44 40 36 Normal pulse rate
8 48 40 44 48 40 40 44 40 44 48 44 40 40 Normal pulse rate
9 88 100 96 96 88 96 64 64 72 70 58 44 44 48 40 44 40 Normal pulse rate
10 40 60 72 64 68 52 56 52 44 52 48 36 44 40 32 36 Normal pulse rate
11 68 60 72 68 52 48 44 56 40 44 40 40 Normal pulse rate
12 44 40 44 40 52 40 44 36 48 48 40 44 36 Normal pulse rate
13 64 64 68 56 56 44 52 48 40 48 44 44 44 36 36 32 Normal pulse rate
14 60 40 48 36 40 40 44 36 40 Normal pulse rate
15 100 72 96 100 82 72 68 64 56 60 52 44 44 52 40 40 Normal pulse rate
16 60 48 48 40 36 48 36 40 Normal pulse rate
17 64 72 76 72 52 52 40 52 48 44 40 48 48 40 36 44 40 44 48 44 44 Normal pulse rate
18 36 48 40 36 32 36 32 Normal pulse rate
19 60 72 60 80 72 48 52 52 56 60 56 52 48 44 40 44 48 40 44 40 Normal pulse rate
20 72 48 56 52 52 44 48 40 40 Normal pulse rate
21 80 72 64 56 60 52 52 48 48 40 44 44 52 48 40 32 Normal pulse rate
22 48 44 44 44 48 40 44 48 40 44 40 36 Normal pulse rate
23 56 52 48 48 52 44 36 28 40 40 36 Normal pulse rate
*Physiological pulse rate (beat/min) in an adult horse: 30–40 [15].
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protocol was used by Fathi et al. [27], who managed to
cure 384/400 glanderous horses and mules by the com-
bined application of sulphonamides given for 30 con-
secutive days with a formolized preparation of B. malleiTable 7 Definition of clinical severity scores modified accordi
Severity score Clinical presentation
0 No pathological signs
1 Unilateral sero-mucous nasal discharge, palpably enl
nodules (n = ≤ 5) on hind quarters with tendency t
debility, exercise intolerance (exercise tolerance test
2 Uni- or bilateral mucopurulent blood-tinged nasal d
sounds from a distance of 3 m), discrete cutaneous
nodes, inappentence (40 % reduction in feed intake
and cough
3 Bilateral blood tinged purulent nasal discharge, conf
from a distance of 7 m), cutaneous nodules and ulc
(pearly cord); visibly enlarged submandibular lymph
joints, exercise intolerance (ETT ≤ 4 min exercise; 3 m
4 Bilateral copious purulent discharge with epistaxis, b
respiratory sounds from a distance of 10 m), cutane
(pearly cords) on trunk/abdomen, legs; oedema of h
inappentence (85 % reduction in feed intake), exercor mallein. Hu et al. used sulphamezathine (sulfadimi-
din) and mallein to treat artificially infected acutely di-
seased horses and asses and apparently cured 41/48 of
the former and 17/23 of the latter [28]. In a more recent
study, Muhammad et al. managed to alleviate clinicalng to [16]
arged submandibular lymph nodes, discrete developing cutaneous
o ulceration on palpation, inappentence (25 % reduction in feed intake),
(ETT) ≤ 12 min exercise 6 min walk + 6 min trot).
ischarge, nasal septum ulcers (n = ≤ 7), mild dyspnea (audible respiratory
nodules and ulcers; slightly to palpably enlarged submandibular lymph
), exercise intolerance (ETT ≤ 8 min exercise; 4 min walk + 4 min trot)
luent nasal septum ulcers, moderate dyspnea (audible respiratory sound
ers in perineal region, groin, medial aspects of thighs with lymphangitis
nodes; inappentence (65% reduction in feed intake) oedema of hock
in walk +1 min trot) and cough
ilateral nasal septum ulcers with perforation, severe dyspnea (audible
ous nodules and ulcers throughout the body, cording of lymphatics
ind quarters and lameness, diagonal spreading in the hind quarters;
ise intolerance (ETT ≤ 2 min exercise; 2 min walk) and cough
Table 8 Comparison of body condition and clinical severity scores during the study period










BCS CSS BCS CSS BCS CSS BCS CSS BCS CSS BCS CSS
1 - 0 - - - - - - - - - - -
2 8 1 7 - - - - - - - - - -
3 7 2 9 - - - - - - - - - -
4 7 3 6 18 0 2 0 - 0 3 0 4 0 Maintained between 4–5 BCS
5 1 4 1 3 0 13 0 8 0 11 0 12 0
6 - 2 0 2 0 9 0 3 0 1 0
7 - - - - - - - - - - - - -
8 - - - - - - - - - - - - -
9 - - - - - - - - - - - - -
BCS: Body condition score; *for optimal performance polo horses are maintained at a level of 5; CSS: Clinical condition score.
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mule) by applying dimethylsulfoxide, a free radical sca-
venger with anti-inflammatory effects and norfloxacin, a
fluoroquinolone antibiotic, for four consecutive days [6].
All animals showed a temporary improvement which
generally lasted for 2–3 weeks. In all studies mentioned
including our own successful outcome was dependant
on duration of therapy. The significance of treatment
duration on disease outcome has also been shown for
small laboratory animals such as mouse and hamster,
and man [1,29,30]. Infected mice treated for ten days
with ceftazidime, a third generation cephalosporin and
levofloxacin, a fluoroquinolone, survived for 34 days,
however treatment did not result in complete clearance
of infection, and bacteria were still found in lungs and
spleens [1]. Likewise, onset of antibiotic treatment after
infection with B. mallei and efficacy of the antibiotic
used influenced disease outcome in hamsters signifi-
cantly [29]. Prolonged treatment duration possibly pre-
vents the establishment of chronic disease. Chronic
glanders as a sequel to non-apparent or non-fatalTable 9 Hematologic values of polo horses with glanders dur
Treatment period (n = 23)
Parameters d 0 d 84
RBC count (1012/1) 3.94 ± 0.78 6.30 ± 0.4
WBC count (109/1) 19.15 ± 4.11 8.10 ± 0.79
Hb [g/dL] 7.918 ± 1.7 11.94 ± 0.69
PCV (ratio) 0.25 ± 0.047 0.38 ± 0.015
ESR (mm/20 min) 126.83 ± 10.40 25.15 ± 2.6
Differential Leukocyte Count
Neutrophils (%) 73.06 ± 9.12 51.0 ± 9.12
Lymphocytes (%) 21.69 ± 6.95 39.7 ± 3.91
Eosinophils (%) 4.77 ± 2.16 3.11 ± 0.57
Monocytes (%) 1.69 ± 1.02 1.52 ± 0.89
Basophils (%) - -infection [24,31] poses a particular challenge to the prac-
titioner as it can go unnoticed for a long period of time.
It is still not clear what causes the “dormant state” and
what triggers off disease. Histopathological studies in
horses assessing samples obtained from glanderous
lesions of the nasal septum have detected bacteria in the
vicinity of extensive accumulations of disintegrating neu-
trophilic granulocytes and macrophages, indicative of
intracellular invasion and survival [32]. However, recent
data obtained from a respiratory cell model suggest that
B. mallei actually induces apoptotic cell death [33]. This
might offer an explanation for the protraction or recur-
rence of disease. Depending on the amount of released
bacteria and the individual immune status of the affected
animal, the disease can continue as a non-apparent in-
fection or exacerbate.
The results of the present study suggest that long term
treatment, i.e. a minimum of 12 weeks, of glanderous
horses with a combination of various antibiotics could
apparently eliminate the pathogenic agent from the
infected animal host. Induction of immunosupression ining the study period
Post treatment observation period (n = 17)
d 180 d 240 d 360
6.80 ± 0.37 7.053 ± 0.29 6.957 ± 0.36
7.91 ± 1.23 7.97 ± 2.14 7.52 ± 1.12
12.79 ± 1.1 13.58 ± 1.0 13.13 ± 1.2
0.41 ± 0.028 0.39 ± 0.025 0.38 ± 0.0 12
21.42 ± 1.94 23.19 ± 2.41 19.89 ± 3.15
50.3 ± 4.39 53.2 ± 3.14 57.28 ± 0.89
47.1 ± 3.01 43.01 ± 2.10 37.5 ± 1.23
2.12 ± 0.76 2.190 ± 0.911 4.23 ± 2.11
1.76 ± 1.40 2.140 ± 1.024 1.2 ± 1.00
- - -
Saqib et al. BMC Veterinary Research 2012, 8:214 Page 10 of 11
http://www.biomedcentral.com/1746-6148/8/214six randomly selected horses did not lead to recrudes-
cence of disease. Moreover, when the treated animals
were returned to the polo club and housed with other
horses, no further cases were reported. Cultivation is
considered a method with low sensitivity, especially in
chronic cases. Under ideal circumstances, one viable
bacterium is hypothetically sufficient for cultivation.
Based on the assumption that immunosupression will
activate infection and the number of viable bacteria is
high, one can assume an increase in sensitivity. In order
to determine the success of treatment is not sufficient to
rely on cultivation results alone; all techniques applied,
i.e. the clinical picture, pathology/necropsy results, micro-
biology, and health status of the sentinel animals must be
evaluated in their entirety.
Of the treated horses, seven are still active at the polo
club and two are kept for breeding purposes and are still
healthy to date (September 2012; data not shown). The
remaining eight were sold and their whereabouts are un-
known to the authors. A further shortcoming of this
study is that no animal was submitted to immunosup-
pressive therapy after the one year observation treatment
to induce recrudescence. However, if the horses were
chronically ill, constant stress due to training and preg-
nancy ought to trigger off acute disease. Ever since this
outbreak, horses at the polo club have been monitored
regularly with the mallein test and none of the treated
animals has been tested positive so far (data not shown).
It must be stressed that any animal (treated or un-
treated) with a positive complement fixation test (CFT)
or positive indirect haemagglutination test (IHAT) is
subject to national and international restrictions and
regulations concerning movement control, re-testing,
quarantine and culling. Of note are the findings that on
day 0, prior to malleinisation, 22/23 horses where posi-
tive in the IHAT, and titres increased further during the
treatment period. One explanation for this rise in titres
is the malleinisation, which is in accordance with pre-
vious findings [34]. A further influencing factor might be
the antibiotic-induced release of B. mallei antigen. The
gradual but continuous decline of the titres could be an
indication of effective and successful therapy.
Although the presented study has shown very promis-
ing results, they must be treated with some caution.
B. mallei strains from the Punjab represent only a small
part of the genetically diverse pathogen [35]. Therefore,
more studies, possibly from small confined outbreaks in
different endemic regions are needed to test if this treat-
ment regime is effective on other B. mallei strains.
Conclusions
One has to bear in mind, that even if this treatment
scheme should prove successful, it is expensive and
therefore only an option in certain situations, e.g.valuable horses, mules, donkeys in wild life conservation
scenarios. In situations in which the affected animal is
the only means of income this long lasting treatment in
unrealistic with regard to cost and control of medica-
tion. A more efficient means of containing spread of di-
sease is to cull the affected animal and provide adequate
compensation.
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